Family History
460 articles
New Study Combines Checkpoint Inhibitors with Radiation Therapy to Boost Immune Response
Dr. Theodore Hong combines checkpoint inhibitors–a type of immunotherapy–with radiation to boost the immune system in pancreatic cancer treatment.
Pancreatic Cancer Patients in the UK Benefit From Unique Precision Medicine Project
Dr. David Chang explains the Precision Panc initiative, a program through the UK’s NHS that helps pancreatic cancer patients find treatments.
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
New Research Sheds Light on Hot and Cold Tumors
Dr. Ben Z. Stanger and his team are finding links between the number of T cells a tumor has and the effectiveness of immunotherapy.
Exercise Helps Boost Immune System and Immunotherapy Treatment
Dr. Emma Kurz is part of a research team that has found that exercise can help make immunotherapy more effective for pancreatic cancer.
Precision Medicine from the Get-Go for Pancreatic Cancer
Dr. Ben George and colleagues at the Medical College of Wisconsin are using molecular profiling to determine the best chemotherapy for a patient’s pancreatic cancer.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
A Liquid Biopsy for Pancreatic Cancer
Dr. Bert Vogelstein and his team at Johns Hopkins are working with a blood test called a liquid biopsy, which tests cells for mutations related to cancer.
CRISPR-Engineered Immunotherapy for Metastatic GI Tract Cancers
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Comparing a Standard Chemotherapy With and Without a PARP Inhibitor
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.